Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, announced participation in the Jefferies Global Healthcare Conference. CEO Elisabet de los Pinos will present on June 6, 2024, at 12:30 p.m. ET. The presentation will be webcast live and available on Aura Biosciences' website, with a replay accessible for 90 days post-event.
- Aura Biosciences is participating in a prestigious global healthcare conference, potentially increasing visibility and investor interest.
- Elisabet de los Pinos, the CEO, will directly present, which might inspire confidence among investors.
- The live webcast and 90-day replay availability ensure extended access to the presentation, potentially engaging a broader audience.
- The press release lacks detailed financial or clinical data, making it hard to assess the immediate impact on stock performance.
- No new information on clinical progress or business developments was disclosed, which might be seen as a missed opportunity for significant updates.
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET.
The live webcast of the presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary uveal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage uveal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
When will Aura Biosciences present at the Jefferies Global Healthcare Conference?
How can I access the Aura Biosciences presentation at the Jefferies Global Healthcare Conference?
What is Aura Biosciences' stock symbol?
